Issue Date: February 22, 2011 Shares of Common Stock (subject to adjustment as provided herein)Common Stock Purchase Warrant • March 31st, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 31st, 2011 Company Industry JurisdictionTHIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED OTHER THAN IN COMPLIANCE WITH REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANTCommon Stock Purchase Warrant • February 1st, 2010 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 1st, 2010 Company Industry JurisdictionBrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Reytalon Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on 24 January, 2012, 1,250,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.50 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.